Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06925750 · ClinicalTrials.gov registry record · Phase 2
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-031/LIGHTRAY EXTENSION)
A Phase 2 study of Pulmonary Arterial Hypertension, sponsored by Merck Sharp & Dohme.
- Active
- Registry status
- Phase 2
- Development phase
- 130
- Enrollment target
- 20
- Study locations
NCT06925750: Active Phase 2 study of Pulmonary Arterial Hypertension, sponsored by Merck Sharp & Dohme.
NCT06925750 is a Phase 2 study of Pulmonary Arterial Hypertension that is active but no longer recruiting, run by Merck Sharp & Dohme. The registered enrollment target is 130 participants, below the 460-participant average among 63 other Pulmonary Arterial Hypertension trials with a reported enrollment target (72% lower). The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06925750, a Phase 2 study of Pulmonary Arterial Hypertension, is active but no longer recruiting, sponsored by Merck Sharp & Dohme.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 130 participants
- Enrollment target
- 20
- Study locations
Study Summary
Researchers are looking for other ways to treat pulmonary arterial hypertension (PAH). Sotatercept is a study medicine that is designed to treat PAH. A past study, MK-7962-024 (LIGHTRAY) (NCT06664801), learned about the safety and effects of sotatercept in people with PAH. One of the goals of that study was to learn about sotatercept when given at a dose (amount) based on the weight range a person is in (weight-banded doses) compared to when given based on a person's exact weight. This is an extension study, which means people who took part in MK-7962-024 (LIGHTRAY) may be able to join this study. In this extension study, people will get weight-banded doses of sotatercept. The main goal of this study is to learn about the safety of weight-banded doses of sotatercept and if people tolerate it over a longer period of time.
Primary Outcome
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience an AE will be reported.
Conditions Studied
Interventions
- BIOLOGICAL Sotatercept
- DRUG Background PAH Therapy
Study Locations (20)
Buenos Aires
- Centro Medico Capital ( Site 0002) - La Plata
- Instituto de Investigaciones Clinicas Mar del Plata ( Site 0006) - Mar del Plata
Other
- Instituto de Cardiologia Juana F. Cabral ( Site 0008) - Corrientes
- Hospital Provincial Jose Maria Cullen ( Site 0005) - Santa Fe
New South Wales
- Royal Prince Alfred Hospital ( Site 0103) - Camperdown
- Westmead Hospital ( Site 0100) - Westmead
Bogota D.C.
- Clinica Colsanitas - Sede Reina Sofia ( Site 0303) - Bogotá
- Fundacion Santa Fe de Bogota ( Site 0302) - Bogotá
Colorado
- University of Colorado Anschutz Medical Campus-University of Colorado Hospital Cardiac and Vascular ( Site 1930) - Aurora
Kansas
- University of Kansas Medical Center ( Site 1928) - Kansas City
New Mexico
- University of New Mexico Health Sciences Center - Department of Internal Medicine ( Site 1916) - Albuquerque
Córdoba Province
- Instituto Medico Rio Cuarto ( Site 0010) - Río Cuarto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2025-05-12 |
| Est. Completion | 2028-06-16 |
| Phase | Phase 2 |
What the registry record for NCT06925750 still lists
NCT06925750 is an interventional study that assigns participants to a tested intervention. The registered 130 participants enrollment target is mid-sized for trials with a published cap, below the 460-participant average among 63 other Pulmonary Arterial Hypertension trials with a reported enrollment target (72% lower).
The record links to 1 condition, with Pulmonary Arterial Hypertension appearing as the primary indexed condition, and to 2 interventions - of which Sotatercept is the first listed.
NCT06925750 names 20 study sites across 16 states, led by Buenos Aires, Other, New South Wales.
Frequently Asked Questions
What is clinical trial NCT06925750 about?
NCT06925750 is a clinical study titled "A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-031/LIGHTRAY EXTENSION)". Researchers are looking for other ways to treat pulmonary arterial hypertension (PAH). Sotatercept is a study medicine that is designed to treat PAH. A past study, MK-7962-024 (LIGHTRAY) (NCT06664801), learned about the safety and effects of sotatercept in people with PAH. One of the goals of that ...
What is the current status of trial NCT06925750?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 130 participants. The study started on 2025-05-12. Estimated completion is 2028-06-16.
What conditions does trial NCT06925750 study?
This clinical trial studies the following conditions: Pulmonary Arterial Hypertension.
What interventions are being tested in trial NCT06925750?
The interventions under investigation include: Sotatercept (BIOLOGICAL), Background PAH Therapy (DRUG).
Who is sponsoring clinical trial NCT06925750?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06925750 being conducted?
This trial has 20 study locations across Colorado, Kansas, New Mexico, Buenos Aires, Córdoba Province. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Arterial Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06925750's enrollment target sits among peer trials
130 16th of 63 higher than 48 of 63 other Pulmonary Arterial Hypertension trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pulmonary Arterial Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
129 Xenon MRI as a Biomarker for Diagnosis and Response to Therapy in Pulmonary Arterial Hypertension (PAH)
RECRUITING · Phase 2
-
Pulmonary Hypertension SOLAR
RECRUITING · Phase 2
-
Xenon MRI Pulm Hypertension
RECRUITING · Phase 2
-
Repurposing Valsartan May Protect Against Pulmonary Hypertension
RECRUITING · Phase 2
-
Spironolactone for Pulmonary Arterial Hypertension
RECRUITING · Phase 2
-
129 Xenon Imaging in Patients Treated With Sotatercept
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01492036 · 130 participants
Long-Term Follow-Up of Recipient of Gene Transfer Research
- NCT01631617 · 130 participants · Phase 2
Effects of Treatments on Atopic Dermatitis
- NCT02368041 · 130 participants
Utility of Thenar Near Infrared Spectroscopy (NIRS) in Pediatric Patients With Heart Failure
- NCT02604277 · 130 participants · NA
Suicidal Behavior in Patients Diagnosed With Bipolar Disorder
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI